Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Jdrf T1D Fund
AddedFeb 13, 2024
UpdatedJun 28, 2026
Jdrf T1D Fund

Jdrf T1D Fund

Operating

JDRF T1D Fund: A NY-based non-profit accelerating type 1 diabetes treatments through early-stage investments.

Location
Boston, MA, US
Founded
2016
Firm
Compare
Portfolio
Employees
Website

Investments

Cour Pharmaceuticals Development
Cour Pharmaceuticals Development

Total Raised

$135.5M

Rounds

4

Series A$105MJanuary 2024
SAB Biotherapeutics
SAB Biotherapeutics
Public

Total Raised

$186.3M

Rounds

8

Post Ipo Equity$130MOctober 2023
Veralox Therapeutics
Veralox Therapeutics

Total Raised

$47.5M

Rounds

4

Series Unknown$24MJune 2023
Series A$16.6MJune 2021
Seed$5.4MSeptember 2019
Code Biotherapeutics
Code Biotherapeutics

Total Raised

$85M

Rounds

2

Series A$75MJune 2022
Seed$10MApril 2021
Kriya Therapeutics
Kriya Therapeutics

Total Raised

$600.5M

Rounds

5

Series C$270MMay 2022
Series B$100MJuly 2021
Series A$80.5MMay 2020
Jaguar Gene Therapy
Jaguar Gene Therapy

Total Raised

$139M

Rounds

3

Series UnknownMarch 2022
Biolinq
Biolinq

Total Raised

$196.3M

Rounds

8

Series B$100MNovember 2021
Series A$4.8MMarch 2019
GentiBio
GentiBio

Total Raised

$177M

Rounds

2

Series A$157MAugust 2021
Sonoma Biotherapeutics
Sonoma Biotherapeutics

Total Raised

$365M

Rounds

4

Series B$265MAugust 2021
Series A$30MSeptember 2020
Abata Therapeutics
Abata Therapeutics

Total Raised

$95M

Rounds

1

Series A$95MJune 2021
Seraxis
Seraxis

Total Raised

$40M

Rounds

1

Series C$40MFebruary 2021
Sonoma Pharmaceuticals
Sonoma Pharmaceuticals
Public

Total Raised

$77.9M

Rounds

5

Post Ipo Equity$70MSeptember 2020
SQZ Biotechnologies
SQZ Biotechnologies
Public

Total Raised

$229.8M

Rounds

14

Series D$65MMay 2020
Series C$72MAugust 2018
i2o Therapeutics
i2o Therapeutics

Total Raised

$90.4M

Rounds

7

Seed$4MApril 2020
Repertoire Immune Medicines
Repertoire Immune Medicines

Total Raised

$257.3M

Rounds

5

Series UnknownMarch 2020
IM Therapeutics
IM Therapeutics

Total Raised

$10M

Rounds

1

Series A$10MOctober 2019
ImmusanT
ImmusanT
Acquired

Total Raised

$72.8M

Rounds

4

Series UnknownSeptember 2018